{"product_id":"hrtx-ansoff-analysis","title":"(HRTX) Heron Therapeutics, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Heron Therapeutics, Inc. Ansoff Matrix Analysis maps the company’s growth options—market penetration, market development, product development, and diversification—and shows how each path applies to its drug portfolio and market positions; the page already includes a real preview\/sample of the analysis so you can assess style and substance before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCINVANTI acute and delayed CINV coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCINVANTI can deepen share in Heron Therapeutics, Inc.'s core chemo-support market by expanding repeat use in oncology centers that already treat chemotherapy-induced nausea and vomiting.\u003c\/p\u003e\n\u003cp\u003eThe IV aprepitant formulation covers both acute and delayed CINV, which helps fit standard antiemetic protocols and supports institutional reordering after first use.\u003c\/p\u003e\n\u003cp\u003eThe market play is conversion, not new category creation: keep turning existing oncology care use into steady hospital and outpatient adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSUSTOL MEC and AC regimen use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSUSTOL’s market penetration in Heron Therapeutics, Inc. comes from deeper use in its labeled settings: nausea and vomiting prevention in moderately emetogenic chemotherapy and anthracycline plus cyclophosphamide regimens. The product’s edge is a single subcutaneous dose of extended-release granisetron, which can simplify prophylaxis versus repeated dosing. That matters because CINV still affects up to 70% to 80% of patients without effective prevention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZYNRELEF postsurgical analgesia adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZYNRELEF is Heron Therapeutics, Inc.'s fixed-dose bupivacaine plus meloxicam product for postsurgical analgesia, and market penetration here means getting more use in the current surgical pain market. In 2025, Heron kept pushing adoption across hospitals and ambulatory surgery centers, where a non-opioid option can fit ERAS protocols and reduce rescue-opioid use. The main test is whether procedure volume and repeat use rise faster than the broader postsurgical pain market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiochronomer single-administration duration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc.’s Biochronomer platform is built to release drug over days to weeks from one dose, which helps it stand out against short-acting products. Penetration is strongest where a longer therapeutic window can cut repeat dosing and support adherence. In 2025, Heron reported net revenue of about $113 million, so proving durable single-dose performance can still matter for growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne dose, days-to-weeks release\u003c\/li\u003e\n\u003cli\u003eTargets short-acting competitors\u003c\/li\u003e\n\u003cli\u003eValue depends on longer exposure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology and surgery portfolio cross-use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. can grow share by pushing existing approved oncology supportive care and postoperative pain products deeper into the same U.S. care pathways. This is pure market penetration: more use of the same portfolio, not new launches. The cross-use angle matters because oncology and surgery overlap at the point of care, where physician and hospital buying decisions are already in place.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse current U.S. care pathways\u003c\/li\u003e\n\u003cli\u003eSell more of approved products\u003c\/li\u003e\n\u003cli\u003eExpand share without new SKUs\u003c\/li\u003e\n\u003cli\u003eTarget oncology and surgery overlap\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeron’s Growth Hinges on Deeper Hospital and Oncology Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. is driving market penetration by pushing CINVANTI, SUSTOL, and ZYNRELEF deeper into existing oncology and surgery workflows. In 2025, Heron reported net revenue of about $113 million, so share gains inside current care pathways matter more than new launches. The play is more repeat use, more hospital adoption, and more reorders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003ePenetration lever\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCINVANTI\u003c\/td\u003e\n\u003ctd\u003eRepeat oncology use\u003c\/td\u003e\n\u003ctd\u003eIV aprepitant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZYNRELEF\u003c\/td\u003e\n\u003ctd\u003eASC and hospital uptake\u003c\/td\u003e\n\u003ctd\u003eNon-opioid pain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Heron Therapeutics, Inc.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps Heron Therapeutics quickly map growth options by reducing strategy guesswork across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography linking Heron Therapeutics' product, market, regulatory, and financial data to support Ansoff Matrix growth decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCINVANTI beyond infusion-center routines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCINVANTI can move beyond infusion-center routines into broader oncology settings that treat highly and moderately emetogenic chemotherapy, using the same approved IV product. It already covers acute and delayed CINV prevention, so this is market development, not a new indication. Heron reported net product sales of $~? \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSUSTOL broader chemotherapy site reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSUSTOL can expand into more chemotherapy delivery settings that use MEC and AC regimens, so the same single-dose, extended-release therapy can reach more hospitals and oncology practices. That fits established antiemetic protocols and supports market development without changing the product itself. For Heron Therapeutics, Inc., the upside comes from wider site penetration and more treated cycles per protocol.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZYNRELEF into more surgical specialties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eZYNRELEF’s 1-dose, 60-hour postsurgical pain control from 2 active drugs gives Heron Therapeutics, Inc. a clear market-development path beyond its current uses. As a commercial dual-acting local anesthetic, it can fit more surgery-based patient groups where opioid-sparing pain control matters. Wider uptake in orthopedic, general, and other specialties could expand addressable procedures without changing the core product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePerioperative care expansion with HTX-019\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHTX-019 moves Heron Therapeutics, Inc. from oncology support into perioperative medicine by targeting postoperative nausea and vomiting (PONV), a setting that affects about 30% of surgical patients and up to 80% of high-risk patients. That makes this an \"market development\" move in the Ansoff Matrix: the same aprepitant-based capability is applied to a new clinical use and buying channel.\u003c\/p\u003e\n\u003cp\u003eIt also widens Heron Therapeutics, Inc.'s addressable market beyond chemotherapy care, where demand is tied to infusion centers, into hospitals and ambulatory surgery centers. In practice, that means one drug platform is being sold into two very different care paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePONV is a new care setting\u003c\/li\u003e\n\u003cli\u003eSame molecule, different market\u003c\/li\u003e\n\u003cli\u003eHospital and ASC demand expands reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. hospital and surgical channel expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. can grow by pushing its same hospital-ready products into more U.S. care sites, not by changing the products themselves. The U.S. has about 6,100 hospitals and roughly 6,500 ambulatory surgery centers, so the reach is still wide for oncology and surgery channels.\u003c\/p\u003e\n\u003cp\u003eThis fits market development because the use case stays the same: procedure-based pain and supportive care in institutional settings. If Heron wins more formulary access, stocking agreements, and perioperative adoption, the same sales base can cover more patient volume across more treatment points.\u003c\/p\u003e\n\u003cp\u003eThe key is channel breadth, since hospital and surgical buyers decide access for large patient groups. That makes U.S. expansion a practical path to scale without needing a new product launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame products, wider U.S. access.\u003c\/li\u003e\n\u003cli\u003eTarget hospitals and surgery centers.\u003c\/li\u003e\n\u003cli\u003eWin formulary and stocking approvals.\u003c\/li\u003e\n\u003cli\u003eExpand oncology and perioperative reach.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeron Expands Approved Drugs Into a Massive U.S. Hospital Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. is using market development by pushing the same approved products into more hospitals, ambulatory surgery centers, and oncology sites. That matters because the U.S. has about 6,100 hospitals and 6,500 ASCs, while PONV affects about 30% of all surgery patients and up to 80% of high-risk cases.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. hospitals\u003c\/td\u003e\n\u003ctd\u003e~6,100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. ASCs\u003c\/td\u003e\n\u003ctd\u003e~6,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePONV rate\u003c\/td\u003e\n\u003ctd\u003e30% to 80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHeron Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report and highlights Heron Therapeutics’ growth options across market penetration, product development, market development, and diversification, with strategic recommendations and risk notes. Buy to unlock the complete, editable file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHTX-019 PONV prevention program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHTX-019 is a development asset for postoperative nausea and vomiting prevention, so it fits Heron Therapeutics, Inc.’s product development move in the Ansoff Matrix. It adds a new antiemetic option to the perioperative portfolio for surgical patients, expanding beyond current offerings. The company is advancing HTX-019 to capture more value in a market where PONV affects up to 30% of all surgical patients and up to 80% of high-risk patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHTX-034 Phase Ib\/II pain program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHTX-034 is a clear product-development move for Heron Therapeutics, Inc. in surgical pain: it is in Phase Ib\/II testing for postoperative pain, including bunionectomy patients. That keeps the asset inside an established care setting and targets a large unmet need, since U.S. outpatient surgeries still number in the tens of millions each year. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiochronomer next-generation formulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc.'s Biochronomer platform supports product development by turning short-acting agents into long-acting injectables, as seen in ZYNRELEF, which provides analgesia for up to 72 hours after one dose. That same controlled-release core can be used to build new therapies with longer duration and fewer repeat doses. In Ansoff terms, it deepens product development around proven technology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDual-acting fixed-dose analgesic design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc.'s ZYNRELEF shows the dual-acting fixed-dose model: bupivacaine plus meloxicam in one shot for postsurgical pain, with analgesia lasting up to 72 hours. That gives Heron a clear product-development path for future single-administration pain drugs, where the key value is longer relief with simpler use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne dose, two mechanisms\u003c\/li\u003e\n\u003cli\u003eUp to 72-hour analgesia\u003c\/li\u003e\n\u003cli\u003eSupports postsurgical use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePerioperative pipeline buildout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. is building its perioperative pipeline to extend the commercial base around pain and nausea. The strategy is product development into adjacent surgical-care needs, using new assets to deepen the reach of its approved portfolio and widen use around procedures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: perioperative pain and nausea\u003c\/li\u003e\n\u003cli\u003eGoal: extend approved products\u003c\/li\u003e\n\u003cli\u003eFit: product development Ansoff play\u003c\/li\u003e\n\u003cli\u003eValue: add assets to the franchise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeron Expands Its Pain Franchise with HTX-019, HTX-034, and ZYNRELEF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. uses Product Development in the Ansoff Matrix by adding HTX-019 and HTX-034 to its perioperative pain and nausea franchise. HTX-019 targets PONV, which affects up to 30% of all surgical patients and up to 80% of high-risk patients, while HTX-034 extends postsurgical pain relief inside the same care setting. ZYNRELEF, with up to 72-hour analgesia from one dose, shows how the Biochronomer platform supports new long-acting products.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTX-019\u003c\/td\u003e\n\u003ctd\u003ePONV\u003c\/td\u003e\n\u003ctd\u003eUp to 80% high-risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTX-034\u003c\/td\u003e\n\u003ctd\u003ePost-op pain\u003c\/td\u003e\n\u003ctd\u003ePhase Ib\/II\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZYNRELEF\u003c\/td\u003e\n\u003ctd\u003ePlatform proof\u003c\/td\u003e\n\u003ctd\u003eUp to 72 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology to perioperative move\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. is shifting from oncology supportive care into surgery, so this is clear diversification. HTX-019 and HTX-034 add 2 perioperative programs beyond its cancer-care base, opening a new therapeutic market with different customers and use cases. That move reduces reliance on one care setting and broadens the company’s product mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePONV entry with HTX-019\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. uses HTX-019 to enter postoperative nausea and vomiting, a market outside its chemotherapy antiemetic base. The move shifts Heron from oncology support into perioperative nausea control, so it is a clear diversification play in the Ansoff Matrix. HTX-019 is the product tied to that entry, and it expands the addressable use case beyond cancer care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePostsurgical pain entry with HTX-034\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHTX-034 is Heron Therapeutics, Inc.'s entry into postoperative pain, a separate care area from its antiemetic franchise. The asset is still in clinical development, so this is a true diversification move into a new market with a new product. It broadens Heron Therapeutics, Inc.'s pipeline beyond nausea control and adds exposure to the large surgical pain segment, where U.S. procedures run into the millions each year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSurgical analgesia franchise with ZYNRELEF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZYNRELEF gives Heron Therapeutics, Inc. a clear diversification move: it shifts the company into surgical pain management, away from its oncology core. The product combines bupivacaine and meloxicam for postsurgical analgesia and can deliver pain relief for up to 72 hours after one dose, creating a second major therapeutic direction.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is diversification because Heron is building in a different treatment area with a distinct surgical customer base. That matters because surgical pain is a large use case, and ZYNRELEF is one of the few dual-acting local anesthetics on the market, giving Heron a differentiated, non-oncology growth lane.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiversifies Heron beyond oncology\u003c\/li\u003e\n\u003cli\u003eTargets postsurgical pain management\u003c\/li\u003e\n\u003cli\u003eUses bupivacaine plus meloxicam\u003c\/li\u003e\n\u003cli\u003eSupports up to 72-hour analgesia\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiochronomer platform across new drug classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiochronomer is a broad controlled-release platform, not tied to one drug class, so Heron Therapeutics, Inc. can adapt it for multiple short-acting agents. That matters because one delivery tech can support several future products and markets, spreading pipeline risk instead of relying on a single therapeutic lane.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWorks across drug classes\u003c\/li\u003e\n\u003cli\u003eSupports controlled release\u003c\/li\u003e\n\u003cli\u003eCan widen future product reach\u003c\/li\u003e\n\u003cli\u003eReduces single-market dependence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeron Therapeutics Expands Beyond Oncology Into Surgical Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeron Therapeutics, Inc. is using diversification to move beyond oncology into perioperative care. ZYNRELEF, HTX-019, and HTX-034 target surgery-linked pain and nausea, so the company is widening its customer base and reducing dependence on one care area.\u003c\/p\u003e\n\u003cp\u003eZYNRELEF delivers up to 72 hours of postsurgical analgesia, while HTX-019 enters postoperative nausea and vomiting, a different market from chemotherapy support. HTX-034 adds another surgical pain pathway, so Heron Therapeutics, Inc. is building a second growth lane.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eZYNRELEF\u003c\/td\u003e\n\u003ctd\u003ePostsurgical pain\u003c\/td\u003e\n\u003ctd\u003eUp to 72-hour relief\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTX-019\u003c\/td\u003e\n\u003ctd\u003ePONV\u003c\/td\u003e\n\u003ctd\u003eOutside oncology use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHTX-034\u003c\/td\u003e\n\u003ctd\u003ePostsurgical pain\u003c\/td\u003e\n\u003ctd\u003ePipeline diversification\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234590105865,"sku":"hrtx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/hrtx-ansoff-matrix.webp?v=1785721178","url":"https:\/\/dcfanalyst.com\/products\/hrtx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}